Skip to content

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here. Hide this message

Laboratory Medicine

Test Directory / Prostate Specific Antigen

Prostate Specific Antigen

Brown clotted serum, gel barrier

TestProstate Specific Antigen
Common AbbreviationsPSA
ProfileNA
Tube typeBrown clotted serum, gel barrier
Clinical IndicationMeasurement of serum PSA in conjunction with Digital Rectal Exam (DRE) is used as an aid in the detection of prostate cancer in men. PSA can also be used to determine the prognosis in patients with prostate cancer and for surveillance and monitoring treatment following diagnosis. After radical prostatectomy PSA levels routinely fall to the undetectable range. If prostatic tissue remains after surgery or metastasis has occurred, PSA is useful in detecting residual and early recurrence of tumour. Serial PSA levels can help determine the success of prostatectomy and the need for further treatment. Benign conditions that can cause elevated PSA levels include benign prostatic hypertrophy, acute and chronic prostatitis, UTI and urinary retention. A number of urological manipulations such as TURP, prostate biopsy, prostate massage and ejaculation may give rise to transient elevated levels.
Specimen TypeBlood
Sample typeSerum
Minimum Volume0.5mL If requesting more than 10 tests please send an additional brown clotted serum sample.
Special PrecautionsNo special requirements
Stability24 hours at 20 - 25°C, 3 days at 2 - 8°C and 24 weeks at -20°C
Turnaround TimeInpatient: 24 hours Outpatient/ GP: 24 hours
LaboratoryYork and Scarborough
Reference IntervalNICE cut off points used as the reference limits: 40-49 years: < 2.0 ng/mL 50-59 years: < 3.0 ng/mL. 60-69 years: < 4.0 ng/mL. Age 70+: < 5.0 ng/mL
LimitationsAnalysis should not be performed on haemolysed, icteric or lipaemic samples. The assay is unaffected by biotin (< 4912 nmol/L or < 1200 ng/mL) No interference was observed from rheumatoid factors up to a concentration of 1500 IU/mL. In vitro tests were performed on 16 commonly used pharmaceuticals. No interference with the assay was found. In addition, special cancer drugs were tested. No interference was found. In rare cases, high titres of antibodies to analyte specific antibodies, streptavidin or ruthenium can occur. Effects minimised by assay design
Notes
Logo on blue with swoosh

Fundraising

Internal hospital signage with arrows to Main Reception, Outpatients and Pharmacy

A-Z of Services

Chinese Poland

View all languages >

Invitation to attend the Trust’s Annual Members Meeting

Trust members and the general public are invited to find out more about their local hospitals by attending the Trust’s virtual Annual Members Meeting (AMM), incorporating the Annual General Meeting (AGM), on Tuesday 26 October 2021, between 11:00am-12:30pm.